Dr. Reddy's Laboratories Limited (RDY)
| Market Cap | 12.33B |
| Revenue (ttm) | 2.99B |
| Net Income (ttm) | 548.26M |
| Shares Out | 166.51M |
| EPS (ttm) | 3.25 |
| PE Ratio | 18.86 |
| Forward PE | 19.53 |
| Dividend | $0.97 (1.31%) |
| Ex-Dividend Date | Jul 28, 2023 |
| Volume | 216,393 |
| Open | 73.40 |
| Previous Close | 70.92 |
| Day's Range | 73.27 - 74.33 |
| 52-Week Range | 53.12 - 77.72 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | 80.00 (+8.08%) |
| Earnings Date | May 8, 2024 |
About RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The ... [Read more]
Full Company ProfileFinancial Performance
In 2022, RDY's revenue was 245.88 billion, an increase of 14.69% compared to the previous year's 214.39 billion. Earnings were 45.07 billion, an increase of 91.22%.
Financial numbers in INR Financial StatementsAnalyst Forecast
According to one analyst, the rating for RDY stock is "Buy" and the 12-month stock price forecast is $80.0.
News
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Avastin--Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
Dr. Reddy's Q3 & 9M FY24 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY24--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2023.
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #AmyrisInc--Dr. Reddy's announces the acquisition of MenoLabs®, a leading women's health and dietary supplements portfolio of brands.
Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DJSIWorld--Dr. Reddy's has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance agen...
Coya Therapeutics, Inc. and Dr. Reddy's Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
HOUSTON & HYDERABAD, India & BASEL, Switzerland--(BUSINESS WIRE)--Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: ...
India's Dr. Reddy's R&D centre being inspected by US FDA
India's Dr Reddy's on Tuesday said that its research and development centre in Hyderabad is being inspected by the U.S. Food and Drug Administration.
Dr. Reddy's Q2 FY24 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended Sep 30, 2023.
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
Dr. Reddy's Q1 FY24 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2023.
Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #BiologicsLicenseApplication--Dr. Reddy's proposed rituximab biosimilar application accepted for review by USFDA, EMA and MHRA.
Dr. Reddy's Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRL_TC--Dr. Reddy's announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study.
Dr. Reddy's Q4 & FY23 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2023.
Dr. Reddy's: A Profitable, Predictable Margin Expander
The Profitable Predictable Margin Expanders screener on GuruFocus has been a helpful one for me when searching for quality stocks that show solid growth. It does what the name suggests - it sorts thro...
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories Ltd. today announced the launch of Regadenoson Injection in the U.S. market.
Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces the launch of Treprostinil Injection in the U.S.
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy's Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg fu...
Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma's U.S. Generic Prescription Product Portfolio
HYDERABAD, India & BASEL, Switzerland & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces agreement to acquire Mayne Pharma's U.S. generic prescription product por...
Dr. Reddy's included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global's Sustainability Yearbook for the 3rd year
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Bloomberg--Dr. Reddy's Laboratories Ltd announced major back-to-back recognitions in gender equality and sustainability.
Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. R...
Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy's”), a global pharmaceutical company, an...
Dr. Reddy's Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy's”), a global pharmaceutical company, an...
World Economic Forum Recognises Dr. Reddy's Hyderabad Factory as Part of its Global Lighthouse Network
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #4IR--World Economic Forum recognises Dr. Reddy's Hyderabad factory as part of its Global Lighthouse Network.
Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Affordablemedicines--Dr. Reddy's Laboratories Ltd. today announced the launch, in the U.S. market, of Lenalidomide Capsules.
Plaintiff in first Zantac lawsuit set for trial drops case
The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.
Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Alcon--Dr. Reddy's Laboratories Ltd. today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayb...